Back to search results

Adjuvant Hypofractionated Stereotactic Radiosurgery for Meningioma

This study is looking at a treatment called hypofractionated stereotactic radiosurgery (SRS) for people who have had surgery for certain types of meningioma. Meningiomas are tumors that form on the membranes covering the brain and spinal cord. This treatment uses high-energy X-rays to precisely target and kill tumor cells. Hypofractionated SRS delivers higher doses of radiation over a shorter time, which might be more effective and have fewer side effects. The study aims to see how safe this treatment is and how well it works in preventing the tumor from coming back. You might be able to join if you are over 18 and have a newly diagnosed Grade 2 meningioma or a Grade 1 meningioma that has returned after treatment. The study plans to enroll 23 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 23 participants.
What's involved
You would receive hypofractionated stereotactic radiosurgery daily for 5 days. You would also have Magnetic Resonance Imaging (MRI) scans throughout the study and may have Computed Tomography (CT) scans if needed.
Compensation
Not stated in the trial record.
Follow-up
The study will track adverse events for up to 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06557512

Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma

Recruiting
NAAges 18+InterventionalTreatment
University of California, San Francisco
~23 participants
Updated 2026-08-26 on ClinicalTrials.gov
What's tested:Hypofractionated Stereotactic Radiosurgery (SRS)Magnetic Resonance Imaging (MRI)Computed Tomography (CT)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of participants with reported adverse events
Measured over Up to 1 year

Conditions

Meningioma
Meningioma, Malignant
Recurrent Meningioma

Explore related trials

Meningioma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • William Chen, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

Francim Aguilar
[email protected]
877-827-3222
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \>+ 18 years at time of study entry
Ability to understand and the willingness to sign a written informed consent document.
Histologic diagnosis of newly diagnosed World Health Organization (WHO) grade 2 or recurrent WHO grade 1 meningioma. With regard to recurrent WHO grade 1 meningioma, participants must present with radiographic evidence of recurrence, and have a histologic diagnosis of WHO grade 1 meningioma at the most recent resection.
Participants must have undergone a gross-total surgical resection as deemed by their neurosurgeon (Simpson grade I-III resection), using all available information which can include post-operative MRI, of a meningioma within 180 days of enrollment.
Participants must have a pre-operative MRI.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Karnofsky score of 70 or higher)
Participants must have post-operative MRI indicating anatomy suitable for hypofractionated radiosurgery, as reviewed by the Radiation Oncology co-principal investigators (PIs).

Exclusion

Concurrent participation in another clinical study with an investigational product unless it is an observational (non-interventional) study or the follow-up period of an interventional study.
Extensive multifocal (3 or more meningiomas) or metastatic disease.
Participants with tumors within 2mm of the optic apparatus or brainstem will be excluded.
Participants with another active primary malignancy or history of previous malignancy (except non-melanoma skin cancers, low and intermediate risk prostate cancers, and in situ cancers such as bladder, gastric, colon, cervical/dysplasia, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period.
Female participants who are pregnant.
Any underlying medical or psychiatric condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results.
Participants with uncontrolled seizures, defined as greater than 3 disabling seizures per day while on anti-epileptic drugs.
Participants who have had previous intracranial radiotherapy overlapping with the area that would be targeted for stereotactic radiosurgery by this study.

What this trial measures

  • Proportion of participants with reported adverse eventsUp to 1 year

    Adverse events will be classified and graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The proportion of CTCAE grade 3-5 toxicity within 1 year of radiation will be estimated along with the exact 90% confidence interval.